UK markets open in 32 minutes

Roche Holding AG (0QQ6.IL)

IOB - IOB Delayed price. Currency in CHF
Add to watchlist
284.20-0.60 (-0.21%)
At close: 09:00PM BST
Full screen
Previous close284.80
YTD returnN/A
Expense ratio (net)N/A
Last cap gainN/A
Morningstar ratingN/A
Morningstar risk ratingN/A
Sustainability ratingN/A
Net assetsN/A
Beta (5Y monthly)N/A
5y average returnN/A
Holdings turnoverN/A
Last dividendN/A
Average for categoryN/A
Inception dateN/A
  • Yahoo Finance Video

    Novo Nordisk, Eli Lilly fall on data from Roche's weight-loss pill

    Shares of Novo Nordisk (NVO) and Eli Lilly (LLY) are sliding after Roche (ROG.SW, RBO.PA) reported promising early-stage trial data from its weight-loss pill. Yahoo Finance Senior Reporter Anjalee Khemlani breaks down the trial results and how the medication may disrupt the current state of the weight-loss drug market as GLP-1 drugs like Novo Nordisk's Ozempic and Eli Lilly's Mounjaro face record demand. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl

  • Business Wire

    Genentech’s Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study

    SOUTH SAN FRANCISCO, Calif., July 17, 2024-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today new, four-year data from the RHONE-X extension study. The study met all primary endpoints, showing that Vabysmo® (faricimab-svoa) was well tolerated in people with diabetic macular edema (DME) who received treatment for up to four years. Exploratory results from the long-term study showed that Vabysmo continued to preserve vision, dry retinal fluid that can impair sigh

  • Globe Newswire

    Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study

    More than 90% of patients had absence of DME after four years in a pre-specified exploratory endpointPeople treated with Vabysmo sustained vision gains and anatomical improvements, with almost 80% receiving treatment at intervals of three or four months, in an exploratory analysis The study met all primary endpoints, showing safety data were consistent with Vabysmo’s known safety profileThis is the largest long-term extension dataset in DME to-date, demonstrating consistent positive results in a